HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target
UroGen Pharma Ltd.
UroGen Pharma Ltd. URGN | 0.00 |
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:
URGN) with a Buy and maintains $45 price target.
